Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
Status:
Not yet recruiting
Trial end date:
2025-11-02
Target enrollment:
Participant gender:
Summary
This study is a post-approval commitment study, and is designed to further evaluate the
safety and efficacy of isavuconazole in a relatively larger Chinese population who will
receive isavuconazole treatment in a post-marketing setting.
This is a single arm, prospective, multi-center study. This study is seeking Chinese patients
with proven, probable or possible Invasive Fungal Disease (IFD) caused by Aspergillus species
or other filamentous fungi. All the participants will receive isavuconazole treatment. The
longest treatment duration in this study is 84 days (up to 180 days for participants
diagnosed with IM).
The primary objective is to characterize the safety and tolerability of isavuconazole through
observing the treatment emergent adverse events.